Table 4

All-cause mortality ratio by Cox regression comparing according to HF phenotype

	HR	95% CI for HR		P value
	HR	Lower	Upper	P value
HFpEF				0.16
HFmrEF	0.88	0.77	1.01	0.07
HFrEF	0.98	0.86	1.12	0.76
<55 years of age				<0.001
55–64 years of age	1.83	1.02	3.28	0.04
65–74 years of age	2.19	1.27	3.76	0.005
75–84 years of age	3.30	1.93	5.65	<0.001
85–95 years of age	4.08	2.37	7.03	<0.001
>95 years of age	4.72	2.49	8.93	<0.001
Man/Women	1.01	0.90	1.12	0.93
eGFR >60 mL/min/1.73 m²				0.008
eGFR 30–59 mL/min/1.73 m²	1.06	0.94	1.20	0.33
eGFR <30 mL/min/1.73 m²	1.31	1.10	1.56	0.002
NT-proBNP elevated	1.66	1.18	2.32	0.003
Hypertension	1.61	1.41	1.85	<0.001
IHD	2.09	1.82	2.39	<0.001
CVI	1.69	1.40	2.03	<0.001
VHD	1.85	1.59	2.16	<0.001
Atrial fibrillation	2.87	2.52	3.28	<0.001
Diabetes mellitus	1.61	1.38	1.87	<0.001
COPD	1.77	1.50	2.08	<0.001
No HF treatment or diuretic only				<0.001
BB or RAASi	0.71	0.62	0.82	<0.001
BB and RAASi	0.52	0.45	0.61	<0.001
BB and RAASi and MRA	0.55	0.47	0.65	<0.001

BB, RAASi and MRA inhibitor treatment within one year after first diagnosed with HF.
ARB, angiotensin receptor blocker; BB, beta-blocker; COPD, chronic obstructive pulmonary disease; CVI, cerebrovascular insult; eGFR, estimated glomerular filtration rate; IHD, ischaemic heart disease; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; RAASI, renin-angiotensin-aldosterone system inhibitor; VHC, valvular heart disease.